Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy

Condition:   Cardiomyopathy, Dilated
Intervention:   Biological: Autologous stem cell therapy
Sponsor:   University Medical Centre Ljubljana
Recruiting - verified May 2015

Human Umbilical Cord Stroma MSC in Myocardial Infarction

Conditions:   Chronic Ischemic Cardiomyopathy;   Coronary Artery Bypass Surgery
Intervention:   Biological: stem cell transplantation
Sponsors:   Ankara University;   Hacettepe University;   Turkiye Yuksek Ihtisas Education and Research Hospital;   ATIGEN-CELL;   Dr. Sami Ulus Children's Hospital;   Yildirim Beyazit University
Recruiting - verified May 2015

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Condition:   Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Interventions:   Drug: Revusiran (ALN-TTRSC);   Drug: Sterile Normal Saline (0.9% NaCl)
Sponsor:   Alnylam Pharmaceuticals
Recruiting - verified May 2015

The Vital Amyloidosis Study, a Phase 3, Multicenter Efficacy and Safety Study of NEOD001

Condition:   Primary Systemic (AL) Amyloidosis
Interventions:   Drug: NEOD001;   Other: Placebo
Sponsor:   Prothena Therapeutics Ltd.
Recruiting - verified May 2015

The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Condition:   Arrhythmogenic Right Ventricular Cardiomyopathy
Intervention:   Device: 80 lead ECG
Sponsor:   The Leeds Teaching Hospitals NHS Trust
Completed - verified May 2015

Budapest Upgrade CRT Study (Version 009-1)

Condition:   Cardiomyopathy
Intervention:   Device: CRT-D
Sponsors:   Bela Merkely;   University of Rochester;   Sheba Medical Center
Enrolling by invitation - verified May 2015

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Condition:   Familial Amyloidotic Cardiomyopathy (FAC)
Intervention:  
Sponsor:   Alnylam Pharmaceuticals
Recruiting - verified May 2015

Safety and Performance of Electrodes Implanted in the Left Ventricle

Conditions:   Heart Failure;   Ventricular Dysfunction;   Cardiomyopathies;   Heart Diseases;   Cardiovascular Diseases
Intervention:   Device: WiCS-LV system
Sponsor:   EBR Systems, Inc.
Active, not recruiting - verified February 2015

Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)

Conditions:   Urea Cycle Disorders,;   Crigler Najjar Syndrome
Intervention:   Biological: HepaStem
Sponsor:   Promethera Biosciences
Completed - verified January 2014

Vitamin D3 Supplementation for Heart Failure Patients

Conditions:   Heart Failure;   Vitamin D Deficiency;   Cardiomyopathy;   Congestive Heart Failure
Interventions:   Drug: Placebo Comparator: Sugar Pill;   Drug: Vitamin D3 (cholecalciferol)
Sponsors:   Heidi Moretti, MS, RD;   Saint Patrick Hospital
Completed - verified May 2015

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

Conditions:   Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP);   Transthyretin Cardiomyopathy (TTR-CM);   Familial Amyloid Cardiomyopathy;   Senile Systemic Amyloidosis (SSA)
Interventions:   Other: No drug;   Other: No drug
Sponsor:   Pfizer
Active, not recruiting - verified May 2015

Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy

Conditions:   Apical Ballooning Syndrome;   Nervous System Diseases, Sympathetic
Interventions:   Drug: Placebo;   Drug: alpha-lipoic acid;   Drug: L-acetyl carnitine
Sponsor:   Second University of Naples
Active, not recruiting - verified May 2015

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

Condition:   TTR-CM
Intervention:   Drug: tafamidis
Sponsor:   Pfizer
Active, not recruiting - verified May 2015

Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

Conditions:   Myocardial Diseases;   Parvovirus B19, Human
Interventions:   Drug: Intravenous Immunoglobulins;   Drug: plasma volume expander
Sponsor:   Sanquin
Recruiting - verified May 2015

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

Condition:   Heart Failure
Interventions:   Biological: Mesenchymal Precursor Cells (MPCs);   Biological: Mesenchymal Precursor Cells (MPCs);   Biological: Mesenchymal Precursor Cells (MPCs);   Procedure: standard-of-care treatment with mock mapping and injection procedures.;   Procedure: standard-of-care treatment with mock mapping and injection procedures.;   Procedure: standard-of-care treatment with mock mapping and injection procedures.
Sponsor:   Mesoblast, Ltd.
Completed - verified May 2015

Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)

Conditions:   Heart Failure;   Coronary Disease;   Heart Valve Diseases;   Cardiomyopathies;   Left Ventricular Hypertrophy
Intervention:  
Sponsor:   Hiroaki Shimokawa, MD, PhD
Active, not recruiting - verified May 2015

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

Conditions:   Ischemic Heart Failure;   Ischemic Heart Disease;   Ischemic Cardiomyopathy
Intervention:   Drug: Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)
Sponsor:   Genzyme, a Sanofi Company
Terminated - verified May 2015

Get CardioSmart

You're Invited